Synta Pharmaceuticals

Synta Pharmaceuticals
Based: Lexington, MA
Founded: Spun off in 2002

Why It's Fierce: In two years Synta has gone from a subsidiary of a Japanese firm to an aggressive, independent up-and-comer with promising drugs in clinical trials and a growing list of top executives. The company has two cancer drugs in development, including multiple Phase II trials of HSP70-Inducer and three candidates for immune disorders. The core scientific team, led by CEO Safi Bahcall, has been operating together for 10 years and new talent is streaming in. Three months ago, Matthew Sherman signed on as chief medical officer coming from Wyeth's research wing. New additions to the company's scientific advisory board have brought in some of the top academic talent from Harvard and King's College.

What to look for: Clinical data to back up its high hopes.

Synta Pharmaceuticals

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.